Patients must live with uncertainty until we have independent scrutiny of key trial data Warfarin reduces the risk of stroke in patients with non-valvular atrial fibrillation but has limitations: a narrow therapeutic window, the need for regular monitoring, and risks of bleeding and drug-drug interactions. Partly because of these limitations, novel oral anticoagulants (NOACs or … More Have clinical trials of NOACs been fair tests of treatments for atrial fibrillation patients?
Here is the video from the SAPC 2016 conference awards session. The main topic of the Yvone Carter award speech is about recent and ongoing work on the NOACs.
Over coagulation with warfarin is associated with an increased risk of bleeding, while under coagulation with an increased risk of thrombosis. Maintaining patients on warfarin within their target INR range reduces this risk, and one way of monitoring this is by calculating their % time in therapeutic range (%TTR). Ideally you would want this to … More Low dose vitamin K to improve INR control